Logo-apb
Adv Pharm Bull. 2018;8(3): 495-505. doi: 10.15171/apb.2018.058
PMID: 30276147        PMCID: PMC6156473

Research Article

Determining Abuse Deterrence Performance of Poly (ethylene oxide) Using a Factorial Design

Yogesh Joshi 1, Srinath Muppalaneni 2, Alborz Omidian 3, David Jude Mastropietro 4 ORCID, Hamid Omidian 4 * ORCID

Cited by CrossRef: 12


1- Barakh Ali S, Dharani S, Afrooz H, Mohamed E, Cook P, Khan M, Rahman Z. Development of Abuse-Deterrent Formulations Using Sucrose Acetate Isobutyrate. AAPS PharmSciTech. 2020;21(3) [Crossref]
2- Gültekin H, Tort S, Tuğcu-Demiröz F, Acartürk F. 3D printed extended release tablets for once daily use: An in vitro and in vivo evaluation study for a personalized solid dosage form. International Journal of Pharmaceutics. 2021;596:120222 [Crossref]
3- Babanejad N, Kandalam U, Omidi Y, Omidian H. Functional properties of thermally tampered poly(ethylene oxide). Bioimpacts. 2022;12(5):471 [Crossref]
4- Hoffmann L, Breitkreutz J, Quodbach J. Hot-Melt Extrusion of the Thermo-Sensitive Peptidomimetic Drug Enalapril Maleate. Pharmaceutics. 2022;14(10):2091 [Crossref]
5- Salem S, Smith D, Byrn S. Degradation products of the abuse deterrent agent Poly(ethylene) oxide under thermal manipulation conditions. Journal of Drug Delivery Science and Technology. 2023;84:104450 [Crossref]
6- Baek J, Shin H, Koo S, Gao Y, Qu H, Feng X, Xu X, Pinto J, Katneni U, Kimchi-Sarfaty C, Buehler P. Polyethylene Oxide Molecular Size Determines the Severity of Atypical Thrombotic Microangiopathy in a Guinea Pig Model of Acute Intravenous Exposure. 2020;177(1):235 [Crossref]
7- Phaugat P, Nishal S, Dhiman R. Abuse-Deterrent Formulations in Constraining the Abuse Potential of Prescription Medicines: A Myth or Truth. CDD. 2022;19(4):466 [Crossref]
8- Babanejad N, Kandalam U, Ahmad R, Omidi Y, Omidian H. Abuse-deterrent properties and cytotoxicity of poly(ethylene oxide) after thermal tampering. International Journal of Pharmaceutics. 2021;600:120481 [Crossref]
9- Bhola J, Borkhataria C. A review on abuse-deterrent formulations: formulation technology and regulatory stands in approval process. Pharmaceutical Development and Technology. 2024;29(8):824 [Crossref]
10- Butreddy A, Sarabu S, Dumpa N, Bandari S, Repka M. Extended release pellets prepared by hot melt extrusion technique for abuse deterrent potential: Category-1 in-vitro evaluation. International Journal of Pharmaceutics. 2020;587:119624 [Crossref]
11- Gad S, Vasiukhina A, Keller J, Solorio L, Yeo Y. Multidimensional opioid abuse deterrence using a nanoparticle-polymer hybrid formulation. Journal of Controlled Release. 2024;370:490 [Crossref]